XML 49 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Revenues (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2021
USD ($)
Component
PerformanceObligation
Revenues [Abstract]      
Revenue $ 131,612 $ 119,497  
WAINUA (Eplontersen) Collaboration with AstraZeneca [Member]      
Revenues [Abstract]      
Upfront payment received     $ 200,000
Number of material components | Component     4
Number of performance obligations | PerformanceObligation     1
Transaction price     $ 200,000
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca 55.00%    
Commercial Revenue [Member]      
Revenues [Abstract]      
Revenue $ 76,168 59,593  
Product Sales, Net [Member]      
Revenues [Abstract]      
Revenue 6,287 0  
TRYNGOLZA [Member]      
Revenues [Abstract]      
Revenue 6,287 0  
Royalty [Member]      
Revenues [Abstract]      
Revenue 64,166 49,385  
SPINRAZA Royalties [Member]      
Revenues [Abstract]      
Revenue 48,010 38,455  
WAINUA Royalties [Member]      
Revenues [Abstract]      
Revenue 9,372 1,125  
Other Royalties [Member]      
Revenues [Abstract]      
Revenue 6,784 9,805  
Other Commercial Revenue [Member]      
Revenues [Abstract]      
Revenue 5,715 10,208  
TEGSEDI and WAYLIVRA Revenue, Net [Member]      
Revenues [Abstract]      
Revenue 5,715 8,628  
Other Revenue [Member]      
Revenues [Abstract]      
Revenue 0 1,580  
Research and Development Revenue [Member]      
Revenues [Abstract]      
Revenue 55,444 59,904  
Collaborative Agreement Revenue [Member]      
Revenues [Abstract]      
Revenue 45,031 49,345  
WAINUA Joint Development Revenue [Member]      
Revenues [Abstract]      
Revenue $ 10,413 $ 10,559